Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Hyperglycemia


Browse the latest news, expert commentary, and educational content on hyperglycemia.


Highlights

12-05-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

07-21-2022 | Sotagliflozin | News

Sotagliflozin effects differ from empagliflozin only at breakfast

The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.

Corticosteroid treatment and the consequences for glucose control

How should clinicians handle hyperglycemia arising from glucocorticoid treatment?

Featured contributor

Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust, UK. 

In this featured article, Prof. Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Read the article

More on hyperglycemia

10-05-2023 | Type 2 diabetes | News

ONWARDS 5: Weekly insulin icodec with app shows real-world promise for type 2 diabetes

10-04-2023 | Hyperglycemia | News

High incidence of alpelisib‐associated hyperglycemia in routine care

07-20-2023 | Type 2 diabetes | News

Triple agonist shows promise for both glycemic and weight control

03-01-2023 | Flash glucose monitoring | News

One-off pre-consultation isCGM use helpful in type 2 diabetes

02-03-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

01-16-2023 | Diet | News

Microbiome support improves type 2 diabetes outcomes

12-13-2022 | Diet | News

Low-carb, high-fat diet gives glycemic benefits in randomized trial

12-05-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

10-25-2022 | Devices and technology | News

Smartphone-delivered CBT improves glycemic control in people with type 2 diabetes
Image Credits